Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492429 | 0.91 | LMNA (0.50) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL5455298 | 0.87 | ENPP2 (0.40) | TP53LMNAF10ENPP2 | |
| SCHEMBL4492374 | 0.86 | F10 (0.52) | TP53LMNAF10ENPP2 | |
| SCHEMBL4500589 | 0.86 | LMNA (0.46) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL4505697 | 0.86 | LMNA (0.48) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL4501332 | 0.85 | F10 (0.53) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL13632168 | 0.84 | TP53 (0.44) | TP53LMNAF10ENPP2 | |
| SCHEMBL4500425 | 0.83 | LMNA (0.46) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL4495243 | 0.82 | TP53 (0.45) | TP53LMNAF10ENPP2ALDH1A1 | |
| SCHEMBL13632171 | 0.82 | GAA (0.41) | TP53LMNAF10ENPP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | PYCR1, OAT, UROD | TP53 3367/4885LMNA 2329/4885F10 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.